Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling

• Main Authors: Dhananjay D. Marathe (Author), Petra M. Jauslin (Author), Huub Jan Kleijn (Author), Carolina deMiranda Silva (Author), Anne Chain (Author), Thomas Bateman (Author), Peter M. Shaw (Author), Anson K. Abraham (Author), Eunkyung A. Kauh (Author), Yanfang Liu (Author), Rodolfo F. Perini (Author), Dinesh P. deAlwis (Author), Lokesh Jain (Author)
• Format: Book
• Published: Wiley, 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Belzutifan (Welireg, Merck & Co., Inc., Rahway, NJ, USA) is an oral, potent inhibitor of hypoxia‐inducible factor 2α, approved for the treatment of certain patients with von Hippel-Lindau (VHL) disease‐associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, and...